From GlobeNewswire: 2025-04-09 13:00:00

The sodium channel blocker market is growing rapidly, with more than 20 pharma companies developing drugs to address neuropathic pain and cardiac arrhythmias. Advances in drug discovery are leading to more selective and effective treatments. DelveInsight’s report highlights key players and promising pipeline drugs like Cenobamate and VX-548.

Key highlights from the report include the FDA granting fast-track designation to LTG-001 for acute pain treatment. RaQualia Pharma reached a development milestone with a novel sodium channel blocker, RQ-00350215. Virios Therapeutics and Wex Pharmaceuticals announced a merger to form Dogwood Therapeutics. Nocion Therapeutics presented data on Taplucainium for Chronic Cough treatment.

Sodium channel blockers are crucial in treating various conditions like cardiac arrhythmias, epilepsy, and chronic pain. They work by blocking sodium channels, reducing neuronal excitability. Drugs like lidocaine and quinidine are widely used in these treatments. DelveInsight’s sodium channel blockers report provides in-depth profiles of pipeline assets and companies.

The report offers a detailed analysis of sodium channel blockers by product type, clinical stage, route of administration, and molecule type. Key companies like SK Biopharmaceuticals and Vertex Pharmaceuticals are developing drugs like Cenobamate and VX-548. DelveInsight’s Pharma Competitive Intelligence Service provides real-time insights for clients to stay ahead in the market.

For more information on sodium channel blockers and related reports, visit DelveInsight’s website. They offer comprehensive insights on epilepsy, refractory epilepsy, and partial epilepsy markets and pipelines. DelveInsight is a trusted business consultant and market research firm specializing in the life sciences industry.



Read more at GlobeNewswire: Sodium Channel Blockers Clinical Trial Pipeline Accelerates